Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome

Prostate

Volumn 29, Issue 3, 1996, Pages 153-158

  Suzuki, Hiroyoshi ^a   Akakura, Koichiro ^a   Komiya, Akira ^a   Aida, Sara ^a   Akimoto, Susumu ^a   Shimazaki, Jun ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

androgen receptor; antiandrogen withdrawal syndrome; genetic alteration; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CHLORMADINONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; EXON; GENE MUTATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TESTICULAR FEMINIZATION; WITHDRAWAL SYNDROME;

AGED; AMINO ACID SEQUENCE; ANDROGEN ANTAGONISTS; CHLORMADINONE ACETATE; CODON; GENES; HUMANS; MALE; MUTATION; ORCHIECTOMY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SUBSTANCE WITHDRAWAL SYNDROME; VARIATION (GENETICS);

EID: 0029825669     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5     Document Type: Article

References (25)

1. Huggins C, Hodges CV: Studies on prostate cancer, effects of castration, of estrogens and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding J-T, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989.
3. Lepor H, Ross A, Walsh PC: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128:335-340, 1982.
4. Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J: State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 85:847-852, 1994.
5. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 174:534-540, 1990.
6. Schuurmans ALG, Bolt J, Voorhorst MM, Blankenstein RA, Mulder E: Regulation of growth and epidermal growth factor receptor levels of prostate tumor cells by different steroids. Int J Cancer 42:917-922, 1988.
7. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765, 1993.
8. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550, 1993.
9. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864, 1994.
10. Castagnaro M, Yandell DW, Dockhorn-Dworhiczak B, Wolfe HJ, Poremba C: Human androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 77:119-123, 1993.
11. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, Tanaka Y, Yamazaki H, Kawada Y, Koiso K, Yoshida O, Kotake T, Yamanaka H, Machida T, Aso Y, Shimazaki J: Comparison of various assay systems for prostate-specific antigen standardization. Jpn J Clin Oncol 22:393-399, 1992.
12. Suzuki H, Sato N, Kodama T, Okano T, Isaka S, Shirasawa H, Simizu B, Shimazaki J: Detection of human papillomvarius DNA and state of p53 gene in Japanese penile cancer. Jpn J Clin Oncol 24:1-6, 1994.
13. Lubahn DB, Brown TR, Simental JA, Higgs HN, Migeon CJ, Wilson EM, French FS: Sequence of the intron/ exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci USA 86:9534-9538, 1989.
14. Lubahn DB, Joseph DR, Sar M, Tan Ja, Higgs HN, Larson RE, French FS, Wilson EM: The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequencing analysis and gene expression in prostate. Mol Endocrinol 2:1265-1275, 1988.
15. Zoppi S, Marcelli M, Deslypere J-P, Griffin JE, Wilson JD, McPhaul MJ: Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance. Mol Endocrinol 6:409-415, 1992.
16. Sai T, Seino S, Chang C, Trifiro M, Pinsky L, Mhatre A, Kaufman M, Lambert B, Trapman J, Brinkmann AO, Rosenfield RL, Liao S: An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity. Am J Hum Genet 46:1095-1100, 1990.
17. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323, 1992.
18. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
19. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993.
20. Akakura K, Akimoto S, Ohki T, Shimazaki J: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45:700-705, 1995.
21. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713, 1992.
22. Sogani PC, Ray B, Whitmore WF Jr: Advanced prostatic carcinoma: Flutamide therapy after conventional endocrine treatment. Urology 6:164-166, 1975.
23. Narayama AS, Loening SA, Culp DA: Flutamide in the treatment of metastatic carcinoma of the prostate. J Urol 53:152-153, 1981.
24. Jordan VC: A therapeutic withdrawal can make a strategic advance. Ann Oncol 3:587-588, 1992.
25. Bezwoda WR, Mansoor N, Dansey R: Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44:345-349, 1987.